Sanofi’s Emerging Markets Steady Despite Venezuela Volatility
Executive Summary
Sanofi reported steady growth in emerging markets in the second quarter despite the volatility in Venezuela and helped by continued momentum in China.
You may also be interested in...
China Growth Rebounds But Pharma Starts Cutting Prices
The second quarter has been a period of stabilization for multinational drug makers in China, where the challenges of cost-cutting and a national policy to encourage domestic generics remain. Big pharmas including Novartis and Roche are voluntarily reduce prices for major products, to help them compete, reflecting a new willingness to improve patient access in the world's second-largest pharma market.
WHO’s Chan Outlines ‘Chinese Dream’ For Health Care Reforms
Relying on general practitioners instead of hospitals and increasing compensation to physicians can solve many health care reform issues in China, says the world's top public health official, who also discusses vaccine scandal in China and Zika infection risks during Rio Olympics.
China Vaccine Scandal: Hundreds Demoted But Root Causes Remain
In a high-profile gesture of showing no tolerance towards poor product quality and management, China has arrested over 200 and punished 357 officials, but root cause of the scandal is much harder to root out in a short term, observers say.